LONDON (Alliance News) - Physiomics PLC Monday said it has signed a contract with a new speciality pharmaceuticals customer to investigate how one of the client's new candidate drugs shrinks tumours.
Physiomics scientists will use systems biology approaches to map the possible pathways by which the drug could act, it said in a statement without giving any financial details. The analysis will be used to narrow down possible mechanisms and suggest new experiments that the client can perform to home in on one mechanism.
"If successful, the directors hope that Physiomics will be able to offer its other modelling services to this new client as the project progresses," the company said in a statement.
Physiomics shares were up 31.6% at 0.25 pence early Monday, the biggest gainer on AIM.
By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.


(Sharecast News) - Physiomics said on Friday that it was making strong operational progress and building the largest commercial pipeline in its histor...


(Sharecast News) - Physiomics said on Friday that it was making strong operational progress and building the largest commercial pipeline in its histor...


(Alliance News) - Physiomics PLC on Friday said it "continues to make strong operational progress" but noted one-off costs from the dismissal of its p...


IN BRIEF: Physiomics wins first contract from Numab Therapeutics


(Sharecast News) - Consultancy firm Physiomics said on Tuesday that it has been awarded a first contract with new client Numab Therapeutics.


Physiomics says full-year results to disappoint market forecasts


AIM WINNERS & LOSERS: Corcel rises on "shovel ready" Tring Road stake


(Sharecast News) - Technology-based solutions provider Physiomics said on Monday that total income for the financial year ending 30 June was likely to...


AIM WINNERS & LOSERS: Tlou Energy rises on project funding hopes


TRADING UPDATES: CentralNic revenue doubles; Augean swing to profit


(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it ann...